{"id":"NCT01546142","sponsor":"Kythera Biopharmaceuticals","briefTitle":"Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area","officialTitle":"Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ATX-101 (Sodium Deoxycholate Injection) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-03","primaryCompletion":"2013-05","completion":"2013-08","firstPosted":"2012-03-07","resultsPosted":"2015-06-15","lastUpdate":"2015-06-15"},"enrollment":516,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Moderate or Severe Submental Fullness"],"interventions":[{"type":"DRUG","name":"Deoxycholic acid injection","otherNames":["ATX-101","Kybella"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Deoxycholic Acid Injection","type":"EXPERIMENTAL"}],"summary":"To evaluate the safety and efficacy of deoxycholic acid injection in the reduction of submental fat (fat below the chin).","primaryOutcome":{"measure":"Percentage of Participants Who Achieved a Composite 1-grade Response","timeFrame":"Baseline and 12 weeks after last treatment (up to 32 weeks after first treatment)","effectByArm":[{"arm":"Deoxycholic Acid Injection","deltaMin":66.5,"sd":null},{"arm":"Placebo","deltaMin":22.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":35,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":258},"commonTop":["Injection site haematoma","Injection site pain","Injection site oedema","Injection site anaesthesia","Injection site erythema"]}}